Pentosan polysulfate treatment of mucopolysaccharidosis type IIIA mice

Ningning Guo, Victor Deangelis, Changzhi Zhu, Edward H. Schuchman, Calogera M. Simonaro

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

11 Scopus citations


Overall Goal: This study was designed to evaluate the impact of pentosan polysulfate (PPS) treatment on mice with mucopolysaccharidosis (MPS) type IIIA (Sanfilippo A syndrome; OMIM 252900). Protocol: Three groups of MPS IIIA mice were evaluated: 1-week-old mice treated with subcutaneous (subQ) PPS at 25 mg/kg once weekly for 31 weeks (group 1); 5-month-old mice treated with subQ PPS once weekly at 50 mg/kg for 12 weeks (group 2); and 5-week-old mice treated by continual intracerebroventricular (ICV) PPS infusion for 11 weeks (60 μg/kg/day). Treated MPS IIIA mice and controls were assessed by measuring plasma cytokine levels, histologic analyses of systemic organs, and analyses of various neuroinflammatory, neurodegenerative, and lysosomal disease markers in their brains. Neurobehavioral testing also was carried out. Results: As seen in other MPS animal models, subQ PPS treatment reduced plasma cytokine levels and macrophage infiltration in systemic tissues. ICV administration did not elicit these systemic effects. SubQ PPS administration also significantly impacted brain neuropathology, inflammation, and behavior. The effect of early subQ treatment was more significant than dose. Surprisingly, ICV PPS treatment had intermediate effects on most of these brain markers, perhaps due to the limited dose and/or duration of treatment. Consistent with these neuropathological findings, we also observed significant improvements in the hyperactivity/anxiety and learning behaviors of the MPS IIIA mice treated with early subQ PPS.

Original languageEnglish
Title of host publicationJIMD Reports
Number of pages16
StatePublished - 2019

Publication series

NameJIMD Reports
ISSN (Print)2192-8304
ISSN (Electronic)2192-8312


  • Central nervous system
  • Mucopolysaccharidosis type IIIA
  • Neuroinflammation
  • Pentosan polysulfate


Dive into the research topics of 'Pentosan polysulfate treatment of mucopolysaccharidosis type IIIA mice'. Together they form a unique fingerprint.

Cite this